AQST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AQST is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has some upside potential if Anaphylm gets back on track, but the current setup is dominated by legal overhang, weak technicals, and no confirmed trading signal. For an impatient buyer, this is not a clean entry.
AQST is in a weak near-term trend. MACD histogram is negative, RSI at 45.15 is neutral, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which signals downward pressure. Price at 4.09 is below the pivot 4.196 and only slightly above support at 4.042, so the stock is sitting near support but has not confirmed a reversal. The short-term pattern data suggests only modest upside probability over the next week and month.
["Oppenheimer initiated coverage with an Outperform rating and $8 target, citing Anaphylm regulatory execution as the key catalyst.", "Alliance Global kept a Buy rating and $9 target, viewing the resubmission path as manageable.", "The March 2026 Type A meeting reportedly gave constructive FDA feedback on PK and human factors study design.", "Revenue in Q4 2025 grew 9.67% year over year."]
["Multiple class action lawsuits and securities fraud investigations were filed in late April and May 2026.", "The FDA issued a Complete Response Letter for Anaphylm, delaying the main catalyst.", "Insiders are selling, and selling increased 140.84% over the last month.", "Hedge funds are neutral with no strong accumulation trend.", "Gross margin declined 10.90% year over year in the latest quarter.", "Analyst price targets were cut previously after the CRL, showing reduced confidence in timing."]
In Q4 2025, revenue rose to $13.02 million, up 9.67% year over year, which is a positive growth sign. However, profitability remains weak: net income was -$31.86 million and EPS was -$0.26, even though both losses improved versus last year. Gross margin fell to 55.16%, down 10.90% year over year, so operational quality is still under pressure.
Recent analyst sentiment is still mostly constructive but cautious. Oppenheimer began coverage with Outperform and an $8 target, while Alliance Global, Leerink, and Lake Street all maintained Buy/Outperform views despite cutting targets after the CRL. The bullish case is that Wall Street sees Anaphylm as a viable approval story with a defined remediation path. The bearish case is that approval timing is delayed, execution risk remains, and the legal/news overhang is now significant.
